The analysis of cardiac troponin I (cTnI) in the diagnosis of myocardial injury in domestic animals is gaining popularity. In this study, equine cTnI was sequenced and compared with previously characterized cTnI from other species. A 6-amino-acid N-terminal deletion unique to the horse was identified. This deletion was outside the epitope region of cTnI recognized by most commercial immunoassays and did not affect the ability of a commercial analyzer system to detect recombinant equine cTnI. No function could be ascribed to the deleted portion. These data support the use of commercial analyzers in measuring equine cTnI.
. Nucleotide sequence of equine cardiac troponin I mRNA. The coding regions are indicated in uppercase letters; the untranslated regions are indicated in lowercase letters.
Troponins are proteins involved in muscular excitationcontraction coupling and are expressed as tissue-specific isoforms. The 3 cardiac troponins-troponin I (cTnI), troponin C (cTnC), and troponin T (cTnT)-form a complex that regulates exposure of myosin-binding sites on cardiac actin in a calcium-dependent manner. 1 Commercial assays have been developed for measurement of the various cardiac troponins in blood after acute myocardial injury. 4 These assays help identify acute myocardial infarcts in humans, and elevated serum troponin concentrations correlate with diagnosis of acute myocardial injury and with prognosis. 1 Previous studies demonstrated cTnI is highly conserved among several diverse mammalian species, 13, 16 allowing veterinarians to measure cTnI in cardiac diseases in animals, including dogs, cats, and horses. 5, 7, 10, 14, 15, 18, 19 Results of immunoassays indicate that only protein from cardiac tissue is specifically detected by these assays in various animal species. 6, 13 Reference ranges for cTnI have been determined for dogs and cats, and in case studies, cTnI was measured in normal horses to establish controls. 5, 18, 21 Veterinary cardiology has witnessed a recent interest in the role of cardiac biomarkers in assessing cardiac status of veterinary patients. 2 Various investigators have examined the ability of atrial or brain natriuretic peptides 3, 8, 9, 12 or of cTnI or cTnT 17, 18, 20, 22 to either identify cardiac disease status or prognosticate on outcome in patients with myocardial damage. In addition, equine myocardial injury with performance or disease has been increasingly investigated by measuring cTnI. 5, 15, 19 The ability to examine these clinical variables relies on specific measurement of these biomarkers, which necessitates their validation.
Recently, cTnI in dogs and cats was cloned and characterized, further validating the use of commercial cTnI immunoassays and providing a baseline for studies of troponin genotypes. 16 The purpose of the present study was to determine the gene sequence of equine cTnI. It was hypothesized that sequence similarity between horses and other mammals would be very high, which would support the use of commercial cTnI detection systems in equine medicine. The equine cTnI sequence would also provide a reference point for studying cTnI polymorphisms in cardiac disease or performance in horses. Although familial dilated cardiomyopathies (DCMs) have not been identified in horses, mutations in cTnI have been implicated in DCM in humans, 11 and comparative studies of cTnI may help elucidate structure/function relationships in healthy and diseased hearts.
The methods used in the present study have been previously described in detail. 16 Briefly, left ventricular myocardial samples were obtained from 3 healthy mixed-breed horses immediately after euthanasia (these animals were euthanatized as part of a separate study, in accordance with Institutional Animal Care and Use Committee protocols). Total RNA was extracted as previously described 11 and used 
Figure 2.
Amino acid sequence alignment of cTnI obtained from horses, cats, dogs, humans, mice, and rats. Amino acids that differed from the consensus sequence (designated as majority) are highlighted. The highlighted portion of the consensus sequence denotes the region commonly targeted by second and third generation troponin I analyzer systems. as a template for the reverse transcription-polymerase chain reaction (RT-PCR) by using several sets of primers (Table  1 ). Thermocycling parameters were as previously described 16 or according to manufacturers' instructions. Initially, upstream and downstream consensus sequence primers based on human, rat, dog, and cat sequences (primer pair 1) ( Table  1) were designed and used for single-step RT-PCR evaluation to obtain the coding sequence. a Then the equine 3Ј untranslated region (UTR) and 5Ј UTR was obtained by Rapid Amplification of cDNA Ends (RACE) using additional primer sets (primer pair 2 and 3) ( Table 1) , according to manufacturer's instructions. b,c Amplicons at all stages were cloned into plasmid vectors before sequencing. d After obtaining the primary sequence for equine cTnI from the first horse, the coding region and bulk of the UTR was cloned and sequenced in 2 additional horses by use of an additional primer pair (primer pair 4) ( Table 1 ). The full coding sequence was then subcloned into a mammalian expression plasmid, e which was used to transiently transfect HEK293T cells. Reverse-cloned control plasmid (cDNA cloned into the plasmid in reverse orientation)was also used to transfect the cells. After 48 hours, the cells were lysed and the cell lysate analyzed for recombinant equine cTnI, as previously described, 16 except for the use of a different transfection reagent f and a different commercial analyzer. g Nucleotide sequencing of equine cTnI cDNA revealed a coding region that was comprised of 618 nucleotides, a 5Ј UTR of 141 nucleotides, and a 3Ј UTR of 48 nucleotides (Fig. 1) . Equine cTnI contained the alanine (Ala 19 ) in the Nterminal region that is present in canine, feline, rat, and murine cTnI (Ala 25 ) but missing from human cTnI. Surprisingly, however, it lacked 6 amino acids in the N-terminal region that are present in all other species studied to date (Fig. 2) . When a motif search engine (http://us.expasy.org/prosite/) was used to ascribe a function to this region, no motif could be attributed to the missing amino acids or surrounding region. The sequence has been submitted to GenBank (accession number AY819020). Equine cTnI shared greatest nu-cleotide and amino acid sequence similarity with canine and feline cTnI (Ͼ90%).
These findings agree with those reported by previous investigators who showed specificity of equine cTnI by Western blotting. 13 The epitopes detected by commercial immunoassays are highly conserved among dogs, cats, humans, and horses, with only 8 amino acid differences after Ala 19/25 (Fig. 2) . Canine and feline cTnI are identical over this region, whereas human and equine cTnI have 4 and 3 differences from the consensus respectively. In support of this observation, equine recombinant cTnI was detected by a commercial cTnI analyzer g (2308.25 ng/ml, reference interval: 0.01 to 0.11 ng/ml; cTnI from control plasmid was below detectable limits).
The present findings substantiate previous clinical reports of cTnI measurement in horses and validate the use of commercial analyzer systems. In addition, the present study provides a baseline for examining cTnI polymorphisms in equine disease and performance 5, 7, 15, 19 and for examining whether equine cTnI demonstrates different kinetic properties from cTnI of other species, which might be ascribed to the deleted 6-amino-acid region. 
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